pharmaphorum

APRIL 27, 2022

AstraZeneca and Daiichi Sankyo have claimed a fifth breakthrough designation from the FDA for Enhertu, shortly after showing the drug extended survival in patients with HER2-low metastatic breast cancer. The post Enhertu gets breakthrough tag in HER2-low breast cancer appeared first on.

Sales 58

Sales Drugs Antibody Licensing 58

Drug Discovery World

APRIL 17, 2023

Totus uses molecular tags that track drug binding in individual cells to screen billions of drug molecules across thousands of genes in parallel, combined with machine learning techniques.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Medicine 52

pharmaphorum

DECEMBER 23, 2021

AZ has already licensed rights to HER2-targeting drug Enhertu (trastuzumab deruxtecan) – which is already on the market for HER2-positive breast and gastric cancers – as well as investigational TROP2 ADC datopotamab deruxtecan in two multibillion-dollar deals. Daiichi Sankyo and AZ are close collaborators in the ADC arena.

Drugs 71

Drugs Antibody Clinical Trials Clinical Trials 71

The Pharma Data

MAY 4, 2021

The findings represent the first comprehensive comparative effectiveness analysis of survival outcomes for a CDK 4/6 inhibitor in routine clinical practice and were published online in Breast Cancer Research. The information contained on our website or any third-party website is not incorporated by reference into this earnings release.

Vaccination 40

Vaccination Vaccine Production Sales 40